论文部分内容阅读
目的观察沙利度胺联合卡培他滨对晚期乳腺癌的疗效及毒性。方法46例Ⅲ～Ⅳ晚期乳腺癌随机分为卡培他滨联合沙利度胺组(A组)和卡培他滨组(B组),A组23例接受卡培他滨2500mg/m2,分早晚两次餐后30min温开水送服,第1～14天,间隔7天,沙利度胺100mg,口服,第1～14天,21天为1周期,化疗4个周期;B组23例不服用沙利度胺。结果A组:CR3例,PR9例,SD8例,PD3例,有效率52.2%,疾病控制率为87%;B组:CR1例,PR4例,SD13例,PD5例,有效率21.7%,疾病控制率为73.9%。结论卡培他滨联合沙利度胺治疗晚期乳腺癌疗效较好,不良反应轻,患者可耐受。
Objective To observe the efficacy and toxicity of thalidomide combined with capecitabine on advanced breast cancer. Methods Forty-six patients with stage Ⅲ-Ⅳ advanced breast cancer were randomly divided into capecitabine plus thalidomide group (group A) and capecitabine group (group B). 23 cases in group A received capecitabine 2500 mg / Sub-morning and evening twice 30min after warm water delivery, the first to 14 days, an interval of 7 days, thalidomide 100mg, orally, 1 to 14 days, 21 days for 1 cycle, chemotherapy 4 cycles; Cases do not take thalidomide. Results In group A, CR3, PR9, SD8 and PD3 had an effective rate of 52.2% and a disease control rate of 87%. Group B: CR1, PR4, SD13, and PD5 achieved an effective rate of 21.7% and disease control The rate was 73.9%. Conclusion Capecitabine combined with thalidomide is effective in the treatment of advanced breast cancer with mild side effects and tolerable in patients.